Northern Trust’s Passage Bio PASG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-14,217
Closed -$168K 4497
2025
Q4
$168K Buy
+14,217
New +$123K ﹤0.01% 4036
2025
Q3
Sell
-5,603
Closed -$44.9K 4511
2025
Q2
$44.9K Buy
5,603
+4
+0.1% +$29 ﹤0.01% 4249
2025
Q1
$39.5K Buy
5,599
+2,475
+79% +$26.8K ﹤0.01% 4260
2024
Q4
$35.4K Buy
3,124
+1,110
+55% +$14.5K ﹤0.01% 4313
2024
Q3
$28.2K Sell
2,014
-1,212
-38% -$19.3K ﹤0.01% 4301
2024
Q2
$51.2K Sell
3,226
-987
-23% -$24.2K ﹤0.01% 4206
2024
Q1
$114K Buy
4,213
+369
+10% +$8.88K ﹤0.01% 4044
2023
Q4
$77.7K Buy
3,844
+1,188
+45% +$16.4K ﹤0.01% 4159
2023
Q3
$34.9K Sell
2,656
-250
-9% -$4.11K ﹤0.01% 4245
2023
Q2
$54.7K Sell
2,906
-139
-5% -$2.75K ﹤0.01% 4202
2023
Q1
$58.3K Buy
3,045
+94
+3% +$2.55K ﹤0.01% 4224
2022
Q4
$81.5K Sell
2,951
-149
-5% -$3.76K ﹤0.01% 4161
2022
Q3
$78K Buy
3,100
+154
+5% +$6.07K ﹤0.01% 4200
2022
Q2
$139K Sell
2,946
-13,170
-82% -$615K ﹤0.01% 4055
2022
Q1
$1M Sell
16,116
-927
-5% -$76.4K ﹤0.01% 3417
2021
Q4
$2.16M Buy
17,043
+645
+4% +$105K ﹤0.01% 3185
2021
Q3
$3.27M Sell
16,398
-706
-4% -$168K ﹤0.01% 3011
2021
Q2
$4.53M Buy
17,104
+1,927
+13% +$596K ﹤0.01% 2899
2021
Q1
$5.31M Buy
15,177
+1,911
+14% +$816K ﹤0.01% 2708
2020
Q4
$6.78M Buy
13,266
+4,720
+55% +$1.89M ﹤0.01% 2493
2020
Q3
$2.24M Buy
8,546
+5,153
+152% +$1.77M ﹤0.01% 3006
2020
Q2
$1.85M Buy
+3,393
New +$1.53M ﹤0.01% 3076

Other funds holding PASG

Northern Trust's PASG Position: Q1 2026 in Review

Northern Trust sold out of Passage Bio (PASG) in Q1 2026, closing a stake of 14,217 shares — an estimated $168K sold.

Northern Trust first reported a position in PASG in Q2 2020 and held it in 22 quarters. The position peaked at $6.78M in Q4 2020. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Northern Trust reported no remaining Passage Bio position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 14,217 Passage Bio shares in Q1 2026, an estimated $168K.
  • Northern Trust first reported a position in Passage Bio in Q2 2020 and held it in 22 quarters.
  • Northern Trust's Passage Bio position peaked at $6.78M in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.